Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0EZLUL
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
US11850287B2 IIIc
|
|||||
| Synonyms |
US11850287B2 IIIc
Click to Show/Hide
|
|||||
| Organization |
ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
5.7
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
IVc
|
|||||